Tenoxicam is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation in joint and muscle conditions. Enocam 20 mg tablet is a brand of tenoxicam from The ACME Laboratories Ltd.
There are 5 brands of Tenoxicam listed in Bangladesh. 3 of them have a lower unit price than Enocam. The lowest listed price is Inoten 20 mg Tablet at ৳ 8.03 per unit.
What is Enocam 20 mg Tablet?
Enocam 20 mg tablet contains tenoxicam, a non-steroidal anti-inflammatory drug (NSAID). It is used for symptomatic treatment of painful inflammatory and degenerative disorders of the musculoskeletal system, including rheumatoid arthritis, osteoarthritis, arthrosis, ankylosing spondylitis, extra-articular disorders such as tendinitis, bursitis, and strains, and acute gout. Tenoxicam works by inhibiting prostaglandin synthesis and has anti-inflammatory, analgesic, and antipyretic properties. The doctor decides the appropriate dose and course for each patient. This medicine should be used only under medical supervision.
Uses of Enocam
Enocam 20 mg tablet is used for symptomatic relief of pain and inflammation in rheumatoid arthritis, osteoarthritis, arthrosis, and ankylosing spondylitis. It is also used for extra-articular disorders like tendinitis, bursitis, periarthritis of shoulders or hips, strains, and sprains, and for acute gout. It belongs to the NSAID class of medicines. The doctor determines if this medicine is suitable for your condition.
How to use Enocam
Take Enocam 20 mg tablet exactly as your doctor prescribes. The dose and duration are decided by the doctor based on your condition. Swallow the tablet with water, preferably at the same time each day if your doctor advises. Do not change the dose or stop treatment without consulting your doctor. If you miss a dose, ask your doctor or pharmacist for guidance. Store the medicine properly and keep it out of reach of children.
Side effects of Enocam
Like all medicines, Enocam 20 mg tablet can cause side effects. Commonly reported effects include stomach and abdominal discomfort, indigestion, heartburn, nausea, dizziness, and headache. Less common effects include constipation. Most side effects are mild and temporary, but if you experience severe or persistent symptoms, contact your doctor. The doctor may adjust treatment if needed. Do not ignore any unusual symptoms while taking this medicine.
Safety and precautions
Enocam 20 mg tablet should not be used if you are allergic to tenoxicam or other NSAIDs, or if you have a history of stomach or duodenal ulcer, gastritis, or aspirin-induced asthma, rhinitis, or urticaria. It may affect kidney function and salt/water balance, so caution is needed in patients with kidney or heart disease, liver cirrhosis, or dehydration. Avoid during the third trimester of pregnancy; breastfeeding mothers should consult their doctor. Inform your doctor about all medicines you take, especially blood thinners, diuretics, or methotrexate. The doctor will decide if it is safe for you.
Frequently asked questions
What does the generic name tenoxicam mean?
Tenoxicam is the generic name of the active ingredient in Enocam 20 mg tablet. It is a non-steroidal anti-inflammatory drug (NSAID). Generic names are standardised names used for the medicine worldwide, while brand names like Enocam are specific to a manufacturer.
What is Enocam 20 mg tablet used for and what kind of medicine is it?
Enocam 20 mg tablet is an NSAID used for symptomatic treatment of painful inflammatory and degenerative musculoskeletal disorders such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, strains, sprains, and acute gout. It helps relieve pain and inflammation. Your doctor will decide if it is appropriate for you.
How should I store Enocam 20 mg tablet?
Store Enocam 20 mg tablet below 30°C, protected from light and moisture. Keep it out of the reach of children. Do not use after the expiry date. Proper storage helps maintain the medicine's quality and safety.
Tenoxicam is indicated for the symptomatic treatment of the following painful inflammatory and degenerative disorders of the musculoskeletal system:
Rheumatoid arthritis.
Osteoarthritis.
Arthrosis.
Ankylosing spondylitis.
Extra-articular disorders, e.g. tendinitis, bursitis, periarthritis of the shoulders (shoulder-hand syndrome) or hips, strains, and sprains.
Acute gout.
Pharmacology
Tenoxicam is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties and it also inhibits platelet aggregation. Tenoxicam inhibits prostaglandin biosynthesis. In-vitro tests of leukocyte peroxidase suggest that tenoxicam may act as a scavenger for active oxygen at the site of inflammation. Tenoxicam is a potent in-vitro inhibitor of human metalloproteinases (stromelysin and collagenase), which induce cartilage breakdown. These pharmacological effects explain, at least in part, the therapeutic benefit of Tenoxicam in the treatment of painful inflammatory and degenerative disorders of the musculoskeletal system. Tenoxicam showed no mutagenic, carcinogenic or teratogenic effects in animals. As with other prostaglandin inhibitors, renal and gastrointestinal effects, increased incidence of dystocia and delayed parturition were observed in animal safety studies.
Dosage & Administration
Standard dosage: For all indications except acute gout, a daily dosage of 20 mg should be given at the same time of day.
In acute attacks of gout: The recommended dose for acute attacks of gout is 40 mg once daily for two days followed by 20 mg once daily for a further five days.
In the treatment of chronic disorders: The therapeutic effect of tenoxicam is evident early in treatment but there is a progressive increase in response over time. In chronic disorders, daily doses higher than 20 mg should be avoided since this would increase the frequency and intensity of unwanted reactions without significantly increasing efficacy. For patients needing long-term treatment, a reduction to a daily oral dose of 10 mg may be tried for maintenance.
Special dosage instructions: In principle, the above dosage recommendations also apply to elderly patients and to patients suffering from kidney or liver disease. Because of lack of clinical experience, no dosage recommendations have so far been established for children and adolescents.
Interaction
As in the case of other NSAIDs, salicylate displaces tenoxicam from protein-binding sites and increases clearance and volume of distribution of tenoxicam. Concurrent treatment with salicylate or other NSAIDs should be avoided because of increased risk of gastrointestinal undesirable reactions. The co-administration of some NSAIDs and methotrexate has been associated with reduced renal tubular secretion of methotrexate, higher plasma concentrations of methotrexate, and severe methotrexate toxicity. Therefore, caution should be exercised when Tenoxicam is administered concurrently with methotrexate. No clinically relevant interaction was found in the small number of patients receiving concomitant treatment with gold, penicillamine or probenecid. As Tenoxicam may decrease the renal clearance of lithium, their concomitant administration may lead to increased plasma levels and toxicity of lithium. The plasma levels of lithium should be closely monitored. As with NSAIDs in general, Tenoxicam should not be administered concurrently with K-sparing diuretics. There is a known interaction between these two classes of compounds, which may cause hyperkalemia and renal failure. No clinically significant interaction between Tenoxicam and furosemide was noted, but Tenoxicam attenuates the blood pressure-lowering effect of hydrochlorothiazide. As known from other NSAIDs, Tenoxicam might attenuate the antihypertensive effects of alpha-adrenergic blockers and ACE-inhibitors. No interactions have been reported between NSAIDs and centrally-acting alpha agonists or calcium channel blockers. There was no clinically relevant interaction when Tenoxicam was administered together with atenolol. During clinical trials no interaction was reported for patients treated concomitantly with digitalis products. Thus concurrent dosing of Tenoxicam and digoxin appears to be without major risk. No interaction has been found with concomitantly administered antacids, cimetidine, warfarin and phenprocoumon at the recommended dosages. The clinical effect of oral antidiabetic drugs (glibornuride, glibenclamide, tolbutamide) was likewise not modified by Tenoxicam. Nevertheless, careful monitoring is recommended when patients concomitantly receive anticoagulants or oral antidiabetic drugs. No clinically relevant interaction has been found between Tenoxicam and low molecular weight heparin.
Contraindications
Tenoxicam must not be administered to patients:
known to be hypersensitive to the drug;
in whom salicylates or other non-steroidal anti-inflammatory drugs (NSAIDs) induce symptoms of asthma, rhinitis, or urticaria;
suffering or having suffered from the disease of the upper gastrointestinal tract, such as gastritis, gastric and duodenal ulcer.
Side Effects
Based on clinical trials including large numbers of patients, Tenoxicam proved to be well tolerated in the recommended dose. Usually, the undesirable effects reported were mild and transient. In a small proportion of patients, the interruption of treatment due to undesirable effects was necessary. Local tolerance of Tenoxicam given parenterally was good. The following undesirable effects have been reported:
Frequency is greater than 1%-
Gastrointestinal tract: gastric, epigastric and abdominal discomfort, dyspepsia, heartburn, nausea.
Central nervous system: dizziness, headache.
Frequency less than 1%-
Gastrointestinal tract: constipation, diarrhea, stomatitis, gastritis, vomiting, ulcers, Gl-bleeding including hematemesis and melena.
Cardiovascular system: elevated blood pressure, mainly in patients treated with cardiovascular drugs.
Liver/Biliary tract: hepatitis.
Pregnancy & Lactation
NSAIDs have an inhibitory effect on prostaglandin synthesis and, when given during late pregnancy, may cause the closure of the fetal ductus arteriosus, prolong labor and delay parturition. Treatment during the third trimester of pregnancy should be avoided. Based on findings from single-dose administration, a very small amount (approximately 0.2%) of tenoxicam passes into breast milk. There is no evidence of adverse reactions in breast-fed infants of mothers taking Tenoxicam. Nevertheless, infants should be weaned or the drug discontinued.
Precautions & Warnings
NSAIDs inhibit renal prostaglandin synthesis and consequently may have an undesirable effect on renal hemodynamics and on salt and water balance. It is necessary to adequately monitor the patient with a special emphasis on cardiac and renal function (BUN, creatinine, development of edema, weight gain, etc.) when giving Tenoxicam to patients with conditions that could increase their risk of developing renal failure, such as pre-existing renal disease, impaired renal function in diabetics, hepatic cirrhosis, congestive heart failure, volume depletion or concomitant treatment with potentially nephrotoxic drugs, diuretics and corticosteroids. Tenoxicam inhibits platelet aggregation and may affect hemostasis. Tenoxicam has no significant influence on blood coagulation factors, coagulation time, prothrombin time or activated thromboplastin time. Patients having coagulation disorders or receiving drug therapy that interferes with hemostasis should, however, be carefully observed when Tenoxicam is administered. Any patient being treated with Tenoxicam who presents with symptoms of gastrointestinal disease should be closely monitored. If peptic ulceration or gastrointestinal bleeding occurs, Tenoxicam should be immediately withdrawn. If severe skin reactions (e.g. Lyell's or Stevens-Johnson syndrome) occur, the treatment should be discontinued immediately. Adverse eye findings have been reported with Tenoxicam. Thus ophthalmic evaluation is recommended for patients who develop visual disturbances. Because of the high plasma protein binding of tenoxicam, caution is required when plasma albumin levels are markedly reduced. In common with anti-inflammatory drugs, Tenoxicam may mask the usual signs of infection. Tenoxicam Tablets should not be given to patients who either dislike or do not tolerate milk products.
Overdose Effects
Although there is no experience of acute overdosage with Tenoxicam, it may be expected that the signs and symptoms mentioned under Undesirable effects would be more pronounced. Overdose should be countered by conventional measures to reduce absorption (e.g. gastrolavage and charcoal) and speed up elimination (e.g. cholestyramine).
Storage Conditions
Do not store above 30°C, protect from light & moisture. Keep out of the reach of children.
Alternative brands of Tenoxicam
Other brands with the same generic name, cheapest first.